REGULATORY

Janssen’s Erleada Clears MHLW Panel Review, Now in Line for March Approval

January 31, 2019
Janssen Pharmaceutical’s prostate cancer drug apalutamide, also known as Erleada overseas, sailed through a key health ministry panel on January 30, opening the way for its approval as early as March. The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) Second…

To read the full story

REGULATORY

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Takashi Ebisawa

A series of drug makers restructured or sold off production facilities in FY2018. Others dissolved or withdrew from the pharmaceutical business altogether. The entry of generics and transfer of products triggered these moves, but the underlying factor was the impact…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…